Keyphrases
Adverse Outcomes
16%
Cardiovascular Disease
16%
Chronic Kidney Disease
100%
Chronic Kidney Disease Patients
16%
Clinical Outcomes
16%
Dialysis
50%
Dialysis Patients
16%
Fibroblast Growth Factor 23 (FGF23)
16%
Human Studies
16%
In Vitro Study
16%
Increased Mortality
16%
Management Strategy
16%
Median Survival
16%
Modification Strategies
16%
Non-dialysis Chronic Kidney Disease
16%
Novel Diagnostics
16%
Novel Therapeutics
16%
Phosphorus Management
33%
Phosphorus Metabolism
100%
Placebo-controlled Randomized Trial
16%
Poor Outcome
16%
Practice Guidelines
16%
Randomized Controlled Trial
16%
Randomized Trial
100%
Rate of Rise
16%
Resignation
16%
Risk Factor Modification
16%
Risk of Death
16%
Risk of Progression
16%
Serum Phosphorus
16%
Medicine and Dentistry
Adverse Outcome
14%
Cardiovascular Disease
14%
Chronic Kidney Disease
100%
Diagnosis
14%
Fibroblast Growth Factor 23
14%
Human Study
14%
In Vitro
14%
Phosphate Metabolism
100%
Placebo
14%
Population
14%
Randomized Controlled Trial
28%
Risk Factor Modification
14%
Neuroscience
Face
66%
Fibroblast Growth Factor 23
33%
In Vitro
33%
Metabolic Pathway
100%
Placebo
33%
Randomized Controlled Trial
66%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Outcome
14%
Cardiovascular Disease
14%
Chronic Kidney Failure
100%
Fibroblast Growth Factor 23
14%
Human Study
14%
Placebo
14%
Randomized Controlled Trial
28%